Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The serotonin 5-hydroxytryptamine receptor 3 (5-HT3) subunit refers to the gene products that constitute the functional 5-HT3 receptor, an ionotropic receptor and cation-selective ligand-gated ion channel of the Cys-loop superfamily[1][2][5]. A functional receptor is formed as a pentameric complex of five subunits, most often identical (homopentameric, typically 5-HT3A) or as heteropentamers (5-HT3A with 5-HT3B-E subunits)[1][2]. These receptor subunits are expressed in both the central and peripheral nervous systems, mediating fast excitatory synaptic transmission and neuronal depolarization in response to serotonin binding[1][2][5][7]. Clinically, 5-HT3 receptor antagonists are widely employed to prevent chemotherapy-induced or postoperative nausea and vomiting, and in treatment of irritable bowel syndrome with diarrhea[4][5]. Subunit composition affects functional properties such as ion selectivity and pharmacology[2][6]. Variants in HTR3A and HTR3B genes may influence individual responses and risk for certain neuropsychiatric disorders[3][5]. **Critical notes:** - The query "Serotonin receptor 5HT3 subunit" is not a canonical target name, but rather refers generically to several different protein subunits (5-HT3A, 5-HT3B, 5-HT3C, 5-HT3D, 5-HT3E), all of which must be specified for structured or pharmacological purposes. - The canonical therapeutic target is the full "Serotonin 5-hydroxytryptamine receptor 3" (5-HT3 receptor), not an individual subunit. - Use of "subunit" without specification is ambiguous and incomplete for database or therapeutic reference[2][5]. **Clarification**: - For structured target information and most pharmacological databases, it is advisable to use "Serotonin 5-hydroxytryptamine receptor 3" or specify the subunit type (e.g., 5-HT3A subunit, 5-HT3B subunit)[1][2][5]. - Therefore, "is_incorrect" is TRUE for the queried form, as it does not specify which subunit and is not the correct canonical form for a therapeutic target.
Antagonism (5-HT3 receptor antagonists block serotonin binding to reduce emetic signaling and neural excitation), Agonism (less common, used in research), Allosteric modulation
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin 5-hydroxytryptamine receptor 3 subunit (5-HT3 receptor subunit).